Research Site

Shertogenbosch 5223 LA

1 studies enrolling now · 20 studies all time

What they study most

Acute Coronary Syndrome, Anemia, Atherothrombosis, Cardiovascular Death, Cardiovascular Disease, Chronic Heart Failure With Reduced Ejection Fraction (HFrEF), Chronic Lymphocytic Leukemia, Chronic Obstructive Pulmonary Disease (COPD), Complicated Intra-Abdominal Infection, Congestive Heart Failure, Diabetes Mellitus, Type 2, Heart Failure

Studies at this site

• Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin — Recruiting now
• Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) — Running, not enrolling
• Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations — Completed
• Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC — Running, not enrolling
• Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy — Running, not enrolling
• Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40% — Completed
• Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL — Running, not enrolling
• Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment. — Completed
• RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial — Completed
• Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS — Completed
• Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction — Completed
• Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer — Completed
• Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure — Completed
• A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus — Completed
• A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis — Stopped early
• Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections — Completed
• Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis — Completed
• ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer — Completed
• Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin — Completed
• A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer — Stopped early